Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.
Oral administration with acyclic retinoid, a synthetic vitamin A analog, for a limited period of 12 months (48 weeks) prevented the development of second primary hepatocellular carcinoma (HCC) and also improved the survival of patients who underwent curative treatments of the initial tumor. Following that randomized controlled study reported in 1996 and 1999, we have continued to follow up the patients by medical imaging and blood chemical analyses, and found that the preventive effect of acyclic retinoid lasted up to 199 weeks after randomization (or 151 weeks after completion of retinoid administration). The retinoid's effect was not mediated by reduction in hepatic necro-inflammation since no significant decrease in serum aminotransferase activity was seen in the retinoid group. Such observation seems quite distinct from the cancer-preventive mechanism of interferon, a potent immunopreventive agent for HCC. We have also shown here the reduction by the retinoid in serum levels of lectin-reactive alpha-fetoprotein (AFP-L3) and protein induced by vitamin K absence or antagonist-II (PIVKA-II), both of which indicate the presence of latent HCC cells. These results suggest that acyclic retinoid may delete such malignant clones before they expand to clinically detectable tumors and thereby inhibited second primary HCC. Once such latent clones are eradicated, it may well take at least several years for the next cancer clone to arise clinically. This may possibly explain a reason for the long-term effect of the retinoid even after the limited period of administration.
Takai
Koji
K
Department of Gastroenterology, Gifu University School of Medicine, Gifu, Japan.
Okuno
Masataka
M
Yasuda
Ichiro
I
Matsushima-Nishiwaki
Rie
R
Uematsu
Takahiro
T
Tsurumi
Hisashi
H
Shiratori
Yoshimune
Y
Muto
Yasutoshi
Y
Moriwaki
Hisataka
H
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D007564:Japan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000517:prevention & control*; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin; D016019:Survival Analysis; D014212:Tretinoin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000509:alpha-Fetoproteins / Q000032:analysis
D000970:Antineoplastic Agents; D015415:Biomarkers; D011498:Protein Precursors; D000509:alpha-Fetoproteins; C008208:acarboxyprothrombin; D014212:Tretinoin; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid; D011516:Prothrombin; D001219:Aspartate Aminotransferases